Galecto Biotech AB is developing galectin-3 inhibitors that target both macrophages and fibroblasts, potentially providing a more complete blockade of fibrosis than Esbriet pirfenidone, the only drug marketed for IPF. The biotech's molecules also may complement other candidates in the IPF pipeline as part of combination therapy.

This month, Galecto secured a €5 million ($6.6 million) extension of its seed financing round, bringing the total to €10 million and enabling the company to get at least through Phase II proof of concept (POC) with its galectin-3 (LGALS3) inhibitor TD139.